Home > Result Summaries: Compounds > abacavir/lamivudine/zidovudine > Result Summary for 112877_5

Result Summary for 112877_5

Result Summary

Protocol ID:	112877_5
Clinical Study ID:	WEUSKOP3368/EPI40320
Official Title:	Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
Phase:	N/A
Study Indications or Diseases:
Generic Name:	abacavir/lamivudine/zidovudine
Trade/Product Name:	Trizivir
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371:1417–26. Law M, Friis-Møller N, Weber R, et al. Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) study. HIV Medicine 2003;4:1-10. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of coronary heart disease (CHD) in HIV-infected patients: The D:A:D CHD risk equation. Session 145, abstract 808. 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007. Los Angeles, California. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. JID 2010;201:318-30